Paper19903552
Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery.
Souto EB and 1 other. Methods Enzymol, 2009. Cited by 60 papers, by iCite.
Cite this record
ConductScience Library. Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Papers, record 19903552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19903552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chapter 6 - Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Chemistry, Pharmaceutical | Major topic |
| Lipids | Major topic |
| Nanoparticles | Major topic |
| Drug Administration Routes | |
| Drug Delivery Systems |
Source PubMed
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 60 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42328129 | Overcoming Biological Barriers: A Comprehensive Review of Advanced Melatonin Delivery Systems for Therapeutic Applications. | Int J Med Sci | 2026 | https://conductscience.org/library/papers/42328129 | PubMed |
| 40115494 | Near-Infrared-Triggered Reversible Transformations of Gold Nanorod-Laden Lipid Assemblies: Implications for Cellular Delivery. | ACS Appl Nano Mater | 2022 | https://conductscience.org/library/papers/40115494 | PubMed |
| 39959643 | Psoriasis: Unraveling Disease Mechanisms and Advancing Pharmacological and Nanotechnological Treatments. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/39959643 | PubMed |
| 39065795 | Advances in Nanomedicine for Precision Insulin Delivery. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39065795 | PubMed |
| 38931816 | Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38931816 | PubMed |
| 38685805 | Evaluation of Melatonin and its Nanostructures Effects on Skin Disorders Focused on Wound Healing. | Mini Rev Med Chem | 2024 | https://conductscience.org/library/papers/38685805 | PubMed |
| 37504455 | Solid Lipid Nanoparticles Embedded Hydrogels as a Promising Carrier for Retarding Irritation of Leflunomide. | Gels | 2023 | https://conductscience.org/library/papers/37504455 | PubMed |
| 36839978 | Current Advances in Lipid Nanosystems Intended for Topical and Transdermal Drug Delivery Applications. | Pharmaceutics | 2023 | https://conductscience.org/library/papers/36839978 | PubMed |
| 35983586 | The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity. | IET Nanobiotechnol | 2022 | https://conductscience.org/library/papers/35983586 | PubMed |
| 35845934 | Anti-CD44 and EGFR Dual-Targeted Solid Lipid Nanoparticles for Delivery of Doxorubicin to Triple-Negative Breast Cancer Cell Line: Preparation, Statistical Optimization, and In Vitro Characterization. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35845934 | PubMed |
| 35198788 | Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. | Heliyon | 2022 | https://conductscience.org/library/papers/35198788 | PubMed |
| 34830774 | Lipid Nanocarriers for Hyperproliferative Skin Diseases. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34830774 | PubMed |
| 34200947 | Melatonin-Loaded Nanocarriers: New Horizons for Therapeutic Applications. | Molecules | 2021 | https://conductscience.org/library/papers/34200947 | PubMed |
| 34067151 | Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34067151 | PubMed |
| 33391000 | Research Progress and Prospect of Nanoplatforms for Treatment of Oral Cancer. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/33391000 | PubMed |
| 32635279 | Properties, Extraction Methods, and Delivery Systems for Curcumin as a Natural Source of Beneficial Health Effects. | Medicina (Kaunas) | 2020 | https://conductscience.org/library/papers/32635279 | PubMed |
| 32244858 | Nanomedicines for the Delivery of Antimicrobial Peptides (AMPs). | Nanomaterials (Basel) | 2020 | https://conductscience.org/library/papers/32244858 | PubMed |
| 32093358 | (+)-Limonene 1,2-Epoxide-Loaded SLNs: Evaluation of Drug Release, Antioxidant Activity, and Cytotoxicity in an HaCaT Cell Line. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32093358 | PubMed |
| 31756981 | Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. | Molecules | 2019 | https://conductscience.org/library/papers/31756981 | PubMed |
| 29844731 | Newly developed controlled release subcutaneous formulation for tramadol hydrochloride. | Saudi Pharm J | 2018 | https://conductscience.org/library/papers/29844731 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19903552
GET https://conductscience.org/api/papers/v1/19903552/cited_by?page=2